Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors

LESSONS LEARNED. Treatment with BEZ235 has not been shown to demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile. The hypothesis of dual targeting of the phosphatidylinositol 3‐kinase and mammalian target of rapamycin pathways in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Salazar, Ramon, Garcia‐Carbonero, Rocio, Libutti, Steven K., Hendifar, Andrew E., Custodio, Ana, Guimbaud, Rosine, Lombard‐Bohas, Catherine, Ricci, Sergio, Klümpen, Heinz‐Josef, Capdevila, Jaume, Reed, Nicholas, Walenkamp, Annemiek, Grande, Enrique, Safina, Sufiya, Meyer, Tim, Kong, Oliver, Salomon, Herve, Tavorath, Ranjana, Yao, James C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058330/
https://www.ncbi.nlm.nih.gov/pubmed/29242283
http://dx.doi.org/10.1634/theoncologist.2017-0144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058330/
https://www.ncbi.nlm.nih.gov/pubmed/29242283
http://dx.doi.org/10.1634/theoncologist.2017-0144

Ejemplares similares